» Articles » PMID: 10027314

Quantification of Tumour Vasculature and Hypoxia by Immunohistochemical Staining and HbO2 Saturation Measurements

Overview
Journal Br J Cancer
Specialty Oncology
Date 1999 Feb 23
PMID 10027314
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the possibility that tumour hypoxia may limit radiotherapeutic response, the underlying mechanisms remain poorly understood. A new methodology has been developed in which information from several sophisticated techniques is combined and analysed at a microregional level. First, tumour oxygen availability is spatially defined by measuring intravascular blood oxygen saturations (HbO2) cryospectrophotometrically in frozen tumour blocks. Second, hypoxic development is quantified in adjacent sections using immunohistochemical detection of a fluorescently conjugated monoclonal antibody (ELK3-51) to a nitroheterocyclic hypoxia marker (EF5), thereby providing information relating to both the oxygen consumption rates and the effective oxygen diffusion distances. Third, a combination of fluorescent (Hoechst 33342 or DiOC7(3)) and immunohistological (PECAM-1/CD31) stains is used to define the anatomical vascular densities and the fraction of blood vessels containing flow. Using a computer-interfaced microscope stage, image analysis software and a 3-CCD colour video camera, multiple images are digitized, combined to form a photo-montage and revisited after each of the three staining protocols. By applying image registration techniques, the spatial distribution of HbO2 saturations is matched to corresponding hypoxic marker intensities in adjacent sections. This permits vascular configuration to be related to oxygen availability and allows the hypoxic marker intensities to be quantitated in situ.

Citing Articles

Characterization of Single-Spheroid Oxygen Consumption Using a Microfluidic Platform and Fluorescence Lifetime Imaging Microscopy.

Kannan S, Peng C, Wu H, Tung Y Biosensors (Basel). 2024; 14(2).

PMID: 38392015 PMC: 10887112. DOI: 10.3390/bios14020096.


Study of oxygen tension variation within live tumor spheroids using microfluidic devices and multi-photon laser scanning microscopy.

Sarkar S, Peng C, Kuo C, Chueh D, Wu H, Liu Y RSC Adv. 2022; 8(53):30320-30329.

PMID: 35546825 PMC: 9085395. DOI: 10.1039/c8ra05505j.


Antitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubbles.

Goertz D, Todorova M, Mortazavi O, Agache V, Chen B, Karshafian R PLoS One. 2013; 7(12):e52307.

PMID: 23284980 PMC: 3527530. DOI: 10.1371/journal.pone.0052307.


Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response.

Fenton B, Paoni S Radiat Res. 2009; 171(5):606-14.

PMID: 19580496 PMC: 2707773. DOI: 10.1667/RR1595.1.


Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumors.

Pattillo C, Venegas B, Donelson F, Del Valle L, Knight L, Chong P Pharm Res. 2009; 26(5):1093-100.

PMID: 19172383 DOI: 10.1007/s11095-009-9826-1.


References
1.
Thomson J, Rauth A . An in vitro assay to measure the viability of KHT tumor cells not previously exposed to culture conditions. Radiat Res. 1974; 58(2):262-76. View

2.
Kayar S, Archer P, Lechner A, Banchero N . The closest-individual method in the analysis of the distribution of capillaries. Microvasc Res. 1982; 24(3):326-41. DOI: 10.1016/0026-2862(82)90020-6. View

3.
Olive P, Durand R . Characterization of a carbocyanine derivative as a fluorescent penetration probe. Cytometry. 1987; 8(6):571-5. DOI: 10.1002/cyto.990080607. View

4.
Smith K, Hill S, BEGG A, Denekamp J . Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer. 1988; 57(3):247-53. PMC: 2246513. DOI: 10.1038/bjc.1988.54. View

5.
Trotter M, Chaplin D, Durand R, Olive P . The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys. 1989; 16(4):931-4. DOI: 10.1016/0360-3016(89)90889-4. View